Page last updated: 2024-11-07

dt 5461

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DT 5461: structure given in first source; DT-5461a is the monomeglumine salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119592
MeSH IDM0207437

Synonyms (7)

Synonym
dt 5461
3-[(2s,3r,4r,5s,6r)-4-[2-(dodecanoylamino)acetyl]oxy-6-[[(2r,3r,4r,5s,6r)-4-[2-(dodecanoylamino)acetyl]oxy-6-(hydroxymethyl)-5-phosphonooxy-3-(tetradecanoylamino)oxan-2-yl]oxymethyl]-5-hydroxy-3-(tetradecanoylamino)oxan-2-yl]oxypentanedioic acid
pentanedioic acid, 3-((2-deoxy-6-o-(2-deoxy-3-o-(((1-oxododecyl)amino)acetyl)-2-((1-oxotetradecyl)amino)-4-o-phosphono-beta-d-glucopyranosyl)-3-o-(((1-oxododecyl)amino)acetyl)-2-((1-oxotetradecyl)amino)-alpha-d-glucopyranosyl)oxy)-
123598-19-6
1,3-dicarboxyisopropyl-2-deoxy-6-o-(2-deoxy-3-o(n-dodecanoylglycyl)-4-o-phosphono-2-tetradecanoylamino-beta-d-glucopyranosyl)-3-o-(n-dodecanoylglycyl)-2-tetradecanoylamino-alpha-d-glucopyranoside
dt-5461
dt-5461a

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies revealed that LPS-induced IL-1 and TNF-alpha production was apparently totally suppressed in a competitive manner by a 10-fold excess of DT-5461."( Endotoxin antagonism by a synthetic lipid A analogue, DT-5461, with low endotoxicity in human peripheral blood monocytes.
Azuma, I; Choon Yoo, Y; Fujihara, M; Hata, K; Sato, K; Sekiguchi, S; Suzuki, T; Takahashi, TA; Tono-Oka, S, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.62 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]